According to filings with the U.S. Securities and Exchange Commission, Affinity Biosensors is raising up to $15,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Affinity Biosensors
LifeScale AST System: Rapid Antimicrobial Susceptibility Testing Same-day reporting from positive blood cultures RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING POPULATION PROFILING DELAYED-GROWTH PHENOTYPES RAPID and PRECISE COUNTS and MASS MEASUREMENT OF INDIVIDUAL MICROBES LOW SAMPLE VOLUME AND CONCENTRATIONS Affinity Biosensors has developed the LifeScale AST system which utilizes mass sensing technology to produce a phenotypic AST result for Gram-negative bacteria directly from a positive blood culture bottle in 4.5 hours. The Companys patented microfluidic sensor measures the mass of individual microbes at the femtogram level. The touchscreen-driven workflow requires minimal hands-on time by the technologist. MIC results are reported as well as SIR interpretive results using CLSI or FDA break-points. Multiple samples can be processed on this bench-top instrument. Reagent kits contain all consumables needed to run one sample and are stable at room temperature. The Gram-negative panel is comprised of 14 antibiotics in a 96-well plate format.

To learn more about Affinity Biosensors, visit http://affinitybio.com/
Affinity Biosensors Linkedin Page: https://www.linkedin.com/company/affinity-biosensors/

Contact:
Kenneth Babcock, Chief Executive Officer
805-455-0181
https://www.linkedin.com/in/ken-babcock-695ab412/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.